Inactive Instrument

Highlights Cytori Therapeutics Inc Nasdaq

Equities

US23283K1051

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

Plus Therapeutics, Inc. Announces Validation & Clinical Implementation of Csf-01 Leptomeningeal Cancer Cell Diagnostic	Mar. 25	CI
Plus Therapeutics Completes Dosing in Cohort 5 of ReSPECT-LM Phase 1 Trial of Rhenium Obisbemeda in Leptomeningeal Metastases	Mar. 11	CI
Plus Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 05	CI
North American Morning Briefing : S&P 500 Futures -2-	Mar. 05	DJ
Plus Therapeutics, Inc. Reports New Interim ReSPECT-GBM Phase 2 Trial Data at the Society for NeuroOncology Annual Meeting	Nov. 20	CI
Plus Therapeutics, Inc. Provides Revenue Guidance for the Fourth Quarter of 2023 and Calendar Year of 2024	23-10-31	CI
Plus Therapeutics, Inc. announces an Equity Buyback for $0.5 million worth of its shares.	23-10-31	CI
Plus Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	23-10-31	CI
Plus Therapeutics, Inc. authorizes a Buyback Plan.	23-10-30	CI
Plus Therapeutics, Inc. Completes Dosing in Cohort 4 of ReSPECT-LM Phase 1 Clinical Trial of Rhenium Obisbemeda in Leptomeningeal Metastases	23-10-10	CI
Biocept Signs Non-Exclusive Licensing Agreement With Plus Therapeutics on CNSide Tumor Cell Platform	23-09-08	MT
Plus Therapeutics, Inc. Initiates Part B of ReSPECT-LM Phase 1/2a Trial for Leptomeningeal Metastase	23-09-05	CI
Tranche Update on Plus Therapeutics, Inc.'s Equity Buyback Plan announced on August 15, 2022.	23-08-14	CI
Tranche Update on Plus Therapeutics, Inc.'s Equity Buyback Plan announced on August 15, 2022.	23-08-14	CI
Plus Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-14	CI
Plus Therapeutics, Inc.'s Equity Buyback announced on August 15, 2022 has expired with 0 shares, representing 0% for $0 million.	23-08-13	CI
Plus Therapeutics Says Leptomeningeal Metastases Phase 1 Trial of Rhenium Obisbemeda Showed Lower Tumor Cell Counts	23-08-11	MT
Plus Therapeutics, Inc. Reports Positive Interim Updates from Two Respect Clinical Trials at SNMMI Annual Meeting	23-06-29	CI
Reverse Split: 1 of 15	23-04-30	FA
Reverse Split: 1 of 15	23-04-30	FA

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Cytori Therapeutics Inc Nasdaq

Equities

US23283K1051

Highlights

Filters